These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 20965712)
1. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712 [TBL] [Abstract][Full Text] [Related]
2. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040 [TBL] [Abstract][Full Text] [Related]
3. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176 [TBL] [Abstract][Full Text] [Related]
4. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120 [TBL] [Abstract][Full Text] [Related]
6. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Huchon G; Magnussen H; Chuchalin A; Dymek L; Gonod FB; Bousquet J Respir Med; 2009 Jan; 103(1):41-9. PubMed ID: 18977646 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961 [TBL] [Abstract][Full Text] [Related]
8. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189 [TBL] [Abstract][Full Text] [Related]
9. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. FitzGerald JM; Boulet LP; Follows RM Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813 [TBL] [Abstract][Full Text] [Related]
11. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results. Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE Drugs; 2009; 69(5):549-65. PubMed ID: 19368417 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing. Kerwin EM; Oppenheimer JJ; LaForce C; Parasuraman B; Miller CJ; O'Dowd L; Goldman M Ann Allergy Asthma Immunol; 2009 Jul; 103(1):62-72. PubMed ID: 19663129 [TBL] [Abstract][Full Text] [Related]
14. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Celli BR; Tashkin DP; Rennard SI; McElhattan J; Martin UJ Respir Med; 2011 Aug; 105(8):1176-88. PubMed ID: 21531124 [TBL] [Abstract][Full Text] [Related]
15. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Lindberg A; Szalai Z; Pullerits T; Radeczky E Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. Busse W; Levine B; Andriano K; Lavecchia C; Yegen U Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS. Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189 [TBL] [Abstract][Full Text] [Related]
20. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]